Immunotherapy holds much promise with its ability to target tumor cells specifically. Building on that promise, doctors and researchers at Seattle Children’s have begun a series of phase 1 trials called BrainChild. These trials test chimeric antigen receptor (CAR) T-cell therapy in children and young adults with recurrent or refractory CNS tumors, including DIPG and DMG.
Read more about how CAR T-cell therapy works.
BrainChild Studies: Phase 1 Trials
Seattle Children’s runs simultaneous clinical trials. This means that rather than waiting for the results of one trial before starting the next one, we share and apply knowledge that we gain from the trials while they are still ongoing. This process significantly speeds up the time spent researching new treatments and cures.